Most placebo patients whose cancer returned later got Libtayo. The trial showed 37% lower death risk.
Regeneron Pharmaceuticals (REGN) presented longer-term data from the Phase 3 C-POST trial, showing Libtayo reduced death risk by 37% in high-risk CSCC patients. The 4-year follow-up confirmed sustained disease-free survival benefits, regardless of minimal residual disease status. Libtayo has been approved in the U.S. and Europe for this indication.
How this was made
The 30-second read
Why it matters
The trial’s survival benefit may expand the drug’s label and drive sales growth, supporting Regeneron's oncology pipeline.
Market read
First disclosure of mature trial data that could materially affect Regeneron's valuation and the broader oncology biotech sector.
What to watch
Potential safety signals, reimbursement challenges, and competition from other PD‑1 inhibitors could temper upside.
Background
Regeneron’s Libtayo is an FDA‑approved PD‑1 inhibitor for several cancers; the C-POST trial adds adjuvant data for high‑risk CSCC.
Ticker impact
Regeneron announced longer-term Phase 3 C-POST trial results showing a 37% lower death risk and improved disease‑free survival for Libtayo in high‑risk cutaneous squamous cell carcinoma.
likely upside as market prices in the survival benefit
First‑report of mature trial data with clear hazard‑ratio improvement; no prior public disclosure.
Market effects
strengthens outlook for oncology biotech sector and PD‑1 inhibitor space
U.S. biotech stocks may see modest gains
could influence global cancer‑drug pipelines and investor sentiment
Counterpoint
If the data does not translate into regulatory label expansions or commercial uptake, the rally may be limited.
Key entities
- companyRegeneron Pharmaceuticals, Inc.
US‑listed biotech developing Libtayo.
- drugLibtayo (cemiplimab)
PD‑1 inhibitor evaluated in the C-POST trial.
